Evidence map›Paper›PMID 42531608›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Renal Tubular Epithelial CRLF1 Interacts With ITGB1 to Accelerate Fibrosis During the Transition From AKI to CKD.

Chunjie Wang, Yan Zhang, Fang Bai, Shankui Qian, Feng Feng, Fangyi Lu, Jiahui Fan, Kuipeng Yu, Xiangdong Yang

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Chunjie WangDepartment of Nephrology, Qilu Hospital of Shandong University, Jinan, Shandong, China.
Yan ZhangDepartment of Neurosurgery, Qilu Hospital, Cheeloo College of Medicine and Institute of Brain and Brain-Inspired Science, Shandong University, Jinan, China.
Fang BaiDepartment of Nephrology, Qilu Hospital of Shandong University, Jinan, Shandong, China.
Shankui QianDepartment of Nephrology, Qilu Hospital of Shandong University, Jinan, Shandong, China.
Feng FengDepartment of Nephrology, Qilu Hospital of Shandong University, Jinan, Shandong, China.
Fangyi LuDepartment of Nephrology, Qilu Hospital of Shandong University, Jinan, Shandong, China.
Jiahui FanDepartment of Nephrology, Qilu Hospital of Shandong University, Jinan, Shandong, China.
Kuipeng YuDepartment of Nephrology, Qilu Hospital of Shandong University, Jinan, Shandong, China.
Xiangdong YangDepartment of Nephrology, Qilu Hospital of Shandong University, Jinan, Shandong, China.ORCID https://orcid.org/0000-0002-5504-9309

Funding

National Natural Science Foundation of China 82270775
6 · The paper itself

Abstract

Acute kidney injury (AKI) frequently progresses to chronic kidney disease (CKD), ultimately leading to end-stage renal failure. Cytokine receptor-like factor 1 (CRLF1) is a secreted protein with low or undetectable expression in normal physiology, but it is transcriptionally and translationally upregulated under pathological conditions. In this study, we found CRLF1 to be upregulated in the kidneys of patients with ATN and CKD, positively correlated with renal interstitial fibrosis, and negatively correlated with renal function. In vivo functional inhibition studies demonstrated that CRLF1 suppression significantly improved renal function, mitigated pathological damage, and delayed fibrosis progression in mouse models of IRI or UUO. Further in vitro studies revealed that CRLF1 promotes fibrosis and inflammation in renal tubular epithelial cells (TECs). Mechanistically, we employed chromatin immunoprecipitation (ChIP) to validate SMAD3 binding to the CRLF1 promoter and its transcriptional regulation, while elevated CRLF1 interacts with the VWFA domain of integrin β1 (ITGB1). Furthermore, transcriptomic sequencing revealed that CRLF1 activates the PI3K/AKT signaling pathway, promoting tubular epithelial cell fibrosis progression via ITGB1. These findings underscore the critical role of CRLF1 in renal fibrosis progression and suggest its potential as a therapeutic target for inhibiting the progression from AKI to CKD.

Indexed as

AKI‐to‐CKD transitionCRLF1fibrosisITGB1SMAD3

Identifiers

PMID42531608
PMCPMC13423483

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.